OTCPK:RYHT.Y

Stock Analysis Report

Executive Summary

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia.

Snowflake

Fundamentals

Established dividend payer with moderate growth potential.


Similar Companies

Share Price & News

How has Ryman Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

RYHT.Y

4.6%

US Healthcare

2.3%

US Market


1 Year Return

5.7%

RYHT.Y

-8.5%

US Healthcare

5.6%

US Market

Return vs Industry: RYHT.Y exceeded the US Healthcare industry which returned -8.5% over the past year.

Return vs Market: RYHT.Y matched the US Market which returned 5.6% over the past year.


Shareholder returns

RYHT.YIndustryMarket
7 Day0%4.6%2.3%
30 Day0%-0.1%-1.0%
90 Day1.0%-4.5%-0.7%
1 Year7.3%5.7%-7.1%-8.5%7.9%5.6%
3 Year36.5%30.7%31.9%26.5%45.6%36.3%
5 Year54.9%44.4%63.7%53.9%65.8%47.6%

Price Volatility Vs. Market

How volatile is Ryman Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Ryman Healthcare undervalued compared to its fair value and its price relative to the market?

20.74x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: RYHT.Y ($43.61) is trading above our estimate of fair value ($20.51)

Significantly Undervalued: RYHT.Y is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RYHT.Y is poor value based on its PE Ratio (20.7x) compared to the Healthcare industry average (20.3x).

PE vs Market: RYHT.Y is poor value based on its PE Ratio (20.7x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: RYHT.Y is poor value based on its PEG Ratio (1.4x)


Price to Book Ratio

PB vs Industry: RYHT.Y is overvalued based on its PB Ratio (3.1x) compared to the US Healthcare industry average (2.5x).


Next Steps

  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Ryman Healthcare forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

14.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RYHT.Y's forecast earnings growth (14.7% per year) is above the savings rate (2.7%).

Earnings vs Market: RYHT.Y's earnings (14.7% per year) are forecast to grow faster than the US market (14.5% per year).

High Growth Earnings: RYHT.Y's earnings are forecast to grow, but not significantly.

Revenue vs Market: RYHT.Y's revenue (11.2% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: RYHT.Y's revenue (11.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: RYHT.Y's Return on Equity is forecast to be low in 3 years time (11.7%).


Next Steps

Past Performance

How has Ryman Healthcare performed over the past 5 years?

11.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: RYHT.Y's earnings have grown by 11.4% per year over the past 5 years.

Accelerating Growth: RYHT.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RYHT.Y had negative earnings growth (-16%) over the past year, making it difficult to compare to the Healthcare industry average (5.3%).


Return on Equity

High ROE: RYHT.Y's Return on Equity (15%) is considered low.


Return on Assets

ROA vs Industry: RYHT.Y's Return on Assets is below or equal to the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: RYHT.Y's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Ryman Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: RYHT.Y's short term assets (NZ$353.0M) do not cover its short term liabilities (NZ$550.6M)

Long Term Liabilities: RYHT.Y's short term assets (353.0M) do not cover its long term liabilities (3.9B)


Debt to Equity History and Analysis

Debt Level: RYHT.Y's debt to equity ratio (61.6%) is considered high

Reducing Debt: RYHT.Y's debt to equity ratio has increased from 30.2% to 61.6% over the past 5 years.

Debt Coverage: RYHT.Y's debt is well covered by operating cash flow (30%).

Interest Coverage: RYHT.Y's interest payments on its debt are not well covered by EBIT (3x coverage).


Balance Sheet

Inventory Level: RYHT.Y has a low level of unsold assets or inventory.

Debt Coverage by Assets: RYHT.Y's debt is not covered by short term assets (assets are 0.3x debt).


Next Steps

Dividend

What is Ryman Healthcare's current dividend yield, its reliability and sustainability?

1.68%

Current Dividend Yield


Dividend Yield vs Market

company1.7%marketbottom25%1.5%markettop25%3.8%industryaverage1.6%forecastin3Years2.2%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: RYHT.Y's dividend (1.68%) is higher than the bottom 25% of dividend payers in the US market (1.46%).

High Dividend: RYHT.Y's dividend (1.68%) is low compared to the top 25% of dividend payers in the US market (3.76%).

Stable Dividend: RYHT.Y's dividends per share have been stable in the past 10 years.

Growing Dividend: RYHT.Y's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (34.8%), RYHT.Y's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: RYHT.Y's dividends in 3 years are forecast to be covered by earnings (50.7% payout ratio).


Next Steps

Management

What is the CEO of Ryman Healthcare's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Gordon MacLeod 0

2.3yrs

Tenure

NZ$1,228,753

Compensation

Mr. Gordon MacLeod has been the Chief Executive Officer since July 1, 2017 of Ryman Healthcare Limited since October 26, 2006 and serves as its Secretary and served as its Deputy Chief Executive and Chief  ...


CEO Compensation Analysis

Compensation vs. Market: Gordon has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Gordon's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

2.3yrs

Average Tenure

Experienced Management: RYHT.Y's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

5.9yrs

Average Tenure

Experienced Board: RYHT.Y's board of directors are considered experienced (5.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Tom Brownrigg

    Chief Construction Officer

    • Tenure: 0yrs
  • Gordon MacLeod

    CEO & Secretary

    • Tenure: 2.3yrs
    • Compensation: NZ$1.23m
  • Debbie Versey McClure

    Chief Sales & Marketing Officer

    • Tenure: 2.8yrs
  • Nicole Forster

    Chief People & Technology Officer

    • Tenure: 0yrs
  • David Bennett

    Chief Financial Officer

    • Tenure: 2.3yrs

Board Members

  • David Kerr

    Independent Chairman of the Board

    • Tenure: 20.8yrs
    • Compensation: NZ$217.00k
  • Simon Challies

    Advisor to the Board

    • Tenure: 2.4yrs
    • Compensation: NZ$2.73m
  • George Savvides

    Non-Executive Director

    • Tenure: 6.8yrs
    • Compensation: NZ$136.01k
  • Warren Bell

    Independent Director

    • Tenure: 8.7yrs
    • Compensation: NZ$125.50k
  • Jo Appleyard

    Non-Executive Director

    • Tenure: 10.8yrs
    • Compensation: NZ$108.00k
  • Claire Higgins

    Non-Executive Director

    • Tenure: 5.1yrs
    • Compensation: NZ$136.01k
  • Anthony Leighs (48yo)

    Independent Director

    • Tenure: 1yrs
    • Compensation: NZ$62.75k
  • Geoff Cumming

    Director

    • Tenure: 1.3yrs
    • Compensation: NZ$90.83k

Company Information

Ryman Healthcare Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ryman Healthcare Limited
  • Ticker: RYHT.Y
  • Exchange: OTCPK
  • Founded: 1984
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: NZ$6.729b
  • Listing Market Cap: NZ$4.218b
  • Shares outstanding: 497.74m
  • Website: https://www.rymanhealthcare.co.nz

Number of Employees


Location

  • Ryman Healthcare Limited
  • Airport Business Park
  • 92 Russley Road
  • Christchurch
  • 8042
  • New Zealand

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RYMNZSE (New Zealand Stock Exchange)YesOrdinary SharesNZNZDJun 1999
RHCG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 1999
RH7DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 1999
RYHT.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDNov 2011

Biography

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. Its villages offer a range of retirement living ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:19
End of Day Share Price2019/09/05 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.